Medpace Holdings Inc
NASDAQ:MEDP

Watchlist Manager
Medpace Holdings Inc Logo
Medpace Holdings Inc
NASDAQ:MEDP
Watchlist
Price: 337.75 USD -1.19% Market Closed
Market Cap: 10.5B USD
Have any thoughts about
Medpace Holdings Inc?
Write Note

Medpace Holdings Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Medpace Holdings Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Medpace Holdings Inc
NASDAQ:MEDP
Net Income (Common)
$365.6m
CAGR 3-Years
26%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Net Income (Common)
$6.1B
CAGR 3-Years
-11%
CAGR 5-Years
11%
CAGR 10-Years
14%
Danaher Corp
NYSE:DHR
Net Income (Common)
$3.9B
CAGR 3-Years
-12%
CAGR 5-Years
10%
CAGR 10-Years
4%
Mettler-Toledo International Inc
NYSE:MTD
Net Income (Common)
$795.6m
CAGR 3-Years
2%
CAGR 5-Years
8%
CAGR 10-Years
9%
Agilent Technologies Inc
NYSE:A
Net Income (Common)
$1.4B
CAGR 3-Years
13%
CAGR 5-Years
6%
CAGR 10-Years
7%
IQVIA Holdings Inc
NYSE:IQV
Net Income (Common)
$1.4B
CAGR 3-Years
22%
CAGR 5-Years
42%
CAGR 10-Years
15%
No Stocks Found

Medpace Holdings Inc
Glance View

Market Cap
10.5B USD
Industry
Life Sciences Tools & Services

Medpace Holdings Inc., a prominent player in the global clinical research organization (CRO) space, has made a name for itself by offering comprehensive drug development services tailored to the needs of pharmaceutical and biotechnology companies. Founded in 1992 and headquartered in Cincinnati, Ohio, the company specializes in conducting clinical trials for innovative therapies across various therapeutic areas, including oncology, cardiology, and infectious diseases. With its unique approach to clinical development, Medpace combines deep operational expertise with a commitment to collaboration and transparency, helping clients navigate the complexities of bringing new drugs to market. The company’s strong track record of successful trial management and regulatory compliance has made it a trusted partner for both established and emerging life sciences firms. As the demand for efficient and effective clinical trials continues to rise in an increasingly competitive market, Medpace is well-positioned for growth. Its focus on ensuring quality and speed enables clients to make faster decisions, which is essential in today's fast-paced healthcare landscape. The company's robust earnings and consistent revenue growth are indicative of its operational excellence and strategic market partnerships. Moreover, with a broad international reach and an experienced workforce, Medpace is adept at adapting to various regulatory environments, further solidifying its reputation as a leader in the CRO industry. For investors, Medpace presents an opportunity to tap into the expanding biopharmaceutical sector, where innovation and patient-centric care are driving demand for clinical development services.

MEDP Intrinsic Value
286.45 USD
Overvaluation 15%
Intrinsic Value
Price

See Also

What is Medpace Holdings Inc's Net Income (Common)?
Net Income (Common)
365.6m USD

Based on the financial report for Sep 30, 2024, Medpace Holdings Inc's Net Income (Common) amounts to 365.6m USD.

What is Medpace Holdings Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
31%

Over the last year, the Net Income (Common) growth was 34%. The average annual Net Income (Common) growth rates for Medpace Holdings Inc have been 26% over the past three years , 31% over the past five years .

Back to Top